2026 Q2 -tulosraportti
19 päivää sitten
‧1 t 2 min
3,75 DKK/osake
Viimeisin osinko
3,89%Tuotto/v
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 -tulosraportti 4.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 -tulosraportti 5.8. | ||
2026 Q1 -tulosraportti 6.5. | ||
Vuosittainen yhtiökokous 2026 26.3. | ||
2025 Q4 -tulosraportti 4.2. | ||
Ylimääräinen yhtiökokous 2025 14.11.2025 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·21 min sittenShocking read. Novo +3%, LLY +70% !
·1 t sittenIt SHALL unconditionally go under 300!!!!!
1 t sittenTHE WOODLANDS, Texas, Aug. 24, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that it has earned a third $10 million milestone payment in 2026 from Novo Nordisk A/S following the achievement of a key patient dosing milestone in the ongoing Phase 1 clinical development program for LX9851, a first-in-class oral small molecule inhibitor of ACSL5 being developed for obesity and associated metabolic disorders. LX9851 is being advanced by Novo Nordisk under the companies' exclusive worldwide license agreement signed in 2025. Under the terms of the agreement, Novo Nordisk obtained an exclusive, worldwide license to develop, manufacture and commercialize LX9851 in all indications. With the achievement of this milestone, Lexicon has now earned $75 million of the $1 billion in potential upfront, development, regulatory and commercial milestone payments available under its collaboration with Novo Nordisk. In addition, Lexicon is entitled to receive tiered royalties on future net sales of LX9851. “This milestone represents another important step forward in the development of LX9851 and further demonstrates the strong execution of our collaboration with Novo Nordisk,” said Mike Exton, CEO and director of Lexicon. “In just over a year, the program has progressed from a licensing agreement to the successful achievement of multiple clinical development milestones. We believe LX9851's novel mechanism and oral profile have the potential to offer an important new approach for people living with obesity and associated metabolic diseases, and we remain excited about the program's continued advancement." The Phase 1 development program for LX9851 was initiated by Novo Nordisk in March 2026 and is investigating the safety, tolerability, pharmacokinetics and pharmacodynamics of single and multiple ascending doses of LX9851 compared to placebo in adult subjects who are overweight or obese. The Phase 1 program is expected to be completed in the first quarter of 2027.
Novo triggers another milestone on LX9851 – a first‑in‑class oral ACSL5‑inhibitor, which can become an important leg in Novo’s post‑semaglutide pipeline. Lexicon has now received 75 mio. USD out of the potential 1 mia., and Phase 1 is running with patient dosing. Small molecules are cheap, oral, and scalable – exactly what Novo needs when the obesity market goes from premium to mass market. Not a GLP‑1‑replacement, but a strategic pipeline‑piece in Novo’s future obesity‑cocktail.
·1 t sitten · MuokattuThe political parties should make it more attractive to invest in Novo Nordisk and other listed companies. Considering the significant risk in stocks, and that shareholders contribute capital to listed companies, the political parties should lower the stock tax (precisely the companies we depend on for our livelihood), so that more Danes dare to place their savings in companies rather than in bank accounts with low returns. In the future, we should not quibble with each other. I belong to this generation that got on the bandwagon, and belong to the privileged, have a home and summer house in the right places, where owning property led to unlimited consumption possibilities. In Denmark, we pride ourselves on the broad shoulders bearing the greatest burden thanks to progressive taxation, but the light cracks in the light of the insane society-created tax-free property gains. It is illogical that one is heavily taxed on salary/stock income and entrepreneurship. The politicians should introduce progressive taxation of property gains (covered by an old Nordic rule, the parcelhusreglen) And use those billions of kroner to reduce tax on work, stock incomes, and entrepreneurship. That is what helps finance our welfare society, what we depend on for our livelihood.It is difficult to change an insane political system. When a large proportion of members of parliament, mayors, and municipal council politicians come from the public sector, where politicians protect a system they themselves are a part of, instead of creating renewal (teachers, pedagogues, academics in the public sector, trade unions), it often favors certain groups. They have experience with the system from within, but often lack insight into private business.,entrepreneurship and market mechanisms.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2026 Q2 -tulosraportti
19 päivää sitten
‧1 t 2 min
3,75 DKK/osake
Viimeisin osinko
3,89%Tuotto/v
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·21 min sittenShocking read. Novo +3%, LLY +70% !
- ·1 t sittenIt SHALL unconditionally go under 300!!!!!
- 1 t sittenTHE WOODLANDS, Texas, Aug. 24, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that it has earned a third $10 million milestone payment in 2026 from Novo Nordisk A/S following the achievement of a key patient dosing milestone in the ongoing Phase 1 clinical development program for LX9851, a first-in-class oral small molecule inhibitor of ACSL5 being developed for obesity and associated metabolic disorders. LX9851 is being advanced by Novo Nordisk under the companies' exclusive worldwide license agreement signed in 2025. Under the terms of the agreement, Novo Nordisk obtained an exclusive, worldwide license to develop, manufacture and commercialize LX9851 in all indications. With the achievement of this milestone, Lexicon has now earned $75 million of the $1 billion in potential upfront, development, regulatory and commercial milestone payments available under its collaboration with Novo Nordisk. In addition, Lexicon is entitled to receive tiered royalties on future net sales of LX9851. “This milestone represents another important step forward in the development of LX9851 and further demonstrates the strong execution of our collaboration with Novo Nordisk,” said Mike Exton, CEO and director of Lexicon. “In just over a year, the program has progressed from a licensing agreement to the successful achievement of multiple clinical development milestones. We believe LX9851's novel mechanism and oral profile have the potential to offer an important new approach for people living with obesity and associated metabolic diseases, and we remain excited about the program's continued advancement." The Phase 1 development program for LX9851 was initiated by Novo Nordisk in March 2026 and is investigating the safety, tolerability, pharmacokinetics and pharmacodynamics of single and multiple ascending doses of LX9851 compared to placebo in adult subjects who are overweight or obese. The Phase 1 program is expected to be completed in the first quarter of 2027.Novo triggers another milestone on LX9851 – a first‑in‑class oral ACSL5‑inhibitor, which can become an important leg in Novo’s post‑semaglutide pipeline. Lexicon has now received 75 mio. USD out of the potential 1 mia., and Phase 1 is running with patient dosing. Small molecules are cheap, oral, and scalable – exactly what Novo needs when the obesity market goes from premium to mass market. Not a GLP‑1‑replacement, but a strategic pipeline‑piece in Novo’s future obesity‑cocktail.
- ·1 t sitten · MuokattuThe political parties should make it more attractive to invest in Novo Nordisk and other listed companies. Considering the significant risk in stocks, and that shareholders contribute capital to listed companies, the political parties should lower the stock tax (precisely the companies we depend on for our livelihood), so that more Danes dare to place their savings in companies rather than in bank accounts with low returns. In the future, we should not quibble with each other. I belong to this generation that got on the bandwagon, and belong to the privileged, have a home and summer house in the right places, where owning property led to unlimited consumption possibilities. In Denmark, we pride ourselves on the broad shoulders bearing the greatest burden thanks to progressive taxation, but the light cracks in the light of the insane society-created tax-free property gains. It is illogical that one is heavily taxed on salary/stock income and entrepreneurship. The politicians should introduce progressive taxation of property gains (covered by an old Nordic rule, the parcelhusreglen) And use those billions of kroner to reduce tax on work, stock incomes, and entrepreneurship. That is what helps finance our welfare society, what we depend on for our livelihood.It is difficult to change an insane political system. When a large proportion of members of parliament, mayors, and municipal council politicians come from the public sector, where politicians protect a system they themselves are a part of, instead of creating renewal (teachers, pedagogues, academics in the public sector, trade unions), it often favors certain groups. They have experience with the system from within, but often lack insight into private business.,entrepreneurship and market mechanisms.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 -tulosraportti 4.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 -tulosraportti 5.8. | ||
2026 Q1 -tulosraportti 6.5. | ||
Vuosittainen yhtiökokous 2026 26.3. | ||
2025 Q4 -tulosraportti 4.2. | ||
Ylimääräinen yhtiökokous 2025 14.11.2025 |
2026 Q2 -tulosraportti
19 päivää sitten
‧1 t 2 min
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 -tulosraportti 4.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 -tulosraportti 5.8. | ||
2026 Q1 -tulosraportti 6.5. | ||
Vuosittainen yhtiökokous 2026 26.3. | ||
2025 Q4 -tulosraportti 4.2. | ||
Ylimääräinen yhtiökokous 2025 14.11.2025 |
3,75 DKK/osake
Viimeisin osinko
3,89%Tuotto/v
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·21 min sittenShocking read. Novo +3%, LLY +70% !
- ·1 t sittenIt SHALL unconditionally go under 300!!!!!
- 1 t sittenTHE WOODLANDS, Texas, Aug. 24, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that it has earned a third $10 million milestone payment in 2026 from Novo Nordisk A/S following the achievement of a key patient dosing milestone in the ongoing Phase 1 clinical development program for LX9851, a first-in-class oral small molecule inhibitor of ACSL5 being developed for obesity and associated metabolic disorders. LX9851 is being advanced by Novo Nordisk under the companies' exclusive worldwide license agreement signed in 2025. Under the terms of the agreement, Novo Nordisk obtained an exclusive, worldwide license to develop, manufacture and commercialize LX9851 in all indications. With the achievement of this milestone, Lexicon has now earned $75 million of the $1 billion in potential upfront, development, regulatory and commercial milestone payments available under its collaboration with Novo Nordisk. In addition, Lexicon is entitled to receive tiered royalties on future net sales of LX9851. “This milestone represents another important step forward in the development of LX9851 and further demonstrates the strong execution of our collaboration with Novo Nordisk,” said Mike Exton, CEO and director of Lexicon. “In just over a year, the program has progressed from a licensing agreement to the successful achievement of multiple clinical development milestones. We believe LX9851's novel mechanism and oral profile have the potential to offer an important new approach for people living with obesity and associated metabolic diseases, and we remain excited about the program's continued advancement." The Phase 1 development program for LX9851 was initiated by Novo Nordisk in March 2026 and is investigating the safety, tolerability, pharmacokinetics and pharmacodynamics of single and multiple ascending doses of LX9851 compared to placebo in adult subjects who are overweight or obese. The Phase 1 program is expected to be completed in the first quarter of 2027.Novo triggers another milestone on LX9851 – a first‑in‑class oral ACSL5‑inhibitor, which can become an important leg in Novo’s post‑semaglutide pipeline. Lexicon has now received 75 mio. USD out of the potential 1 mia., and Phase 1 is running with patient dosing. Small molecules are cheap, oral, and scalable – exactly what Novo needs when the obesity market goes from premium to mass market. Not a GLP‑1‑replacement, but a strategic pipeline‑piece in Novo’s future obesity‑cocktail.
- ·1 t sitten · MuokattuThe political parties should make it more attractive to invest in Novo Nordisk and other listed companies. Considering the significant risk in stocks, and that shareholders contribute capital to listed companies, the political parties should lower the stock tax (precisely the companies we depend on for our livelihood), so that more Danes dare to place their savings in companies rather than in bank accounts with low returns. In the future, we should not quibble with each other. I belong to this generation that got on the bandwagon, and belong to the privileged, have a home and summer house in the right places, where owning property led to unlimited consumption possibilities. In Denmark, we pride ourselves on the broad shoulders bearing the greatest burden thanks to progressive taxation, but the light cracks in the light of the insane society-created tax-free property gains. It is illogical that one is heavily taxed on salary/stock income and entrepreneurship. The politicians should introduce progressive taxation of property gains (covered by an old Nordic rule, the parcelhusreglen) And use those billions of kroner to reduce tax on work, stock incomes, and entrepreneurship. That is what helps finance our welfare society, what we depend on for our livelihood.It is difficult to change an insane political system. When a large proportion of members of parliament, mayors, and municipal council politicians come from the public sector, where politicians protect a system they themselves are a part of, instead of creating renewal (teachers, pedagogues, academics in the public sector, trade unions), it often favors certain groups. They have experience with the system from within, but often lack insight into private business.,entrepreneurship and market mechanisms.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt